CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 185.5 AUD 0.96% Market Closed
Market Cap: 90B AUD

CSL Ltd
Depreciation & Amortization

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

CSL Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
CSL Ltd
ASX:CSL
Depreciation & Amortization
-$468m
CAGR 3-Years
-69%
CAGR 5-Years
N/A
CAGR 10-Years
-34%
Opthea Ltd
ASX:OPT
Depreciation & Amortization
-$91k
CAGR 3-Years
-5%
CAGR 5-Years
1%
CAGR 10-Years
-9%
Mesoblast Ltd
ASX:MSB
Depreciation & Amortization
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Depreciation & Amortization
-AU$1.2m
CAGR 3-Years
-16%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Depreciation & Amortization
-AU$600.1k
CAGR 3-Years
11%
CAGR 5-Years
-2%
CAGR 10-Years
-11%
No Stocks Found

CSL Ltd
Glance View

In the bustling world of biotech innovation, CSL Limited stands as a stalwart, renowned for not just navigating but shaping the industry's intricate landscape. Founded in 1916, this Australian giant has grown from its humble beginnings to become a global leader in the biopharmaceutical sector. CSL operates primarily through two main segments: CSL Behring and Seqirus. CSL Behring is the cornerstone of the company's growth, specializing in the development of life-saving therapies derived from human plasma. These therapies are pivotal in treating rare and serious diseases such as hemophilia, immune deficiencies, and hereditary angioedema. The company has built an impressive collection of facilities across several continents, focusing on plasma collection and processing, which underscores its commitment to advanced therapeutic solutions. Alongside CSL Behring, Seqirus has emerged as a formidable force in the influenza vaccine market and is now one of the world's largest flu vaccine providers. The acquisition and transformation of this division signify CSL’s strategic expansion into broader preventive healthcare. From developing and distributing advanced technologies in cell-based and adjuvanted influenza vaccines to advancing research in universal flu vaccines, Seqirus exemplifies CSL's innovative spirit. Collectively, these divisions illustrate how CSL marries cutting-edge research with robust global operations to generate robust revenues, addressing pressing healthcare needs across the globe while promising new horizons in medical science.

CSL Intrinsic Value
HIDDEN
Show

See Also

What is CSL Ltd's Depreciation & Amortization?
Depreciation & Amortization
-468m USD

Based on the financial report for Jun 30, 2025, CSL Ltd's Depreciation & Amortization amounts to -468m USD.

What is CSL Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
-34%

Over the last year, the Depreciation & Amortization growth was -14%. The average annual Depreciation & Amortization growth rates for CSL Ltd have been -69% over the past three years , and -34% over the past ten years .

Back to Top